Ziishera是一个新的HER2疗法,促进了晚期胃癌病人的存活,促进了库存收益和2026年林业发展局提交的呈文。 Ziihera, a new HER2 therapy, boosted survival in advanced stomach cancer patients, prompting stock gains and a 2026 FDA submission.

Jazz制药公司和Zymeworks公司在第三阶段试验后看到库存激增,显示Ziiehera是HER2定向疗法,大大改善了HER2抗体阳性先进胃炎性肾上腺癌患者在接受化疗时的无进展和总体存活率,无论是否使用PD-1抑制剂。 Jazz Pharmaceuticals and Zymeworks saw their stocks surge after a Phase 3 trial showed Ziihera, a HER2-targeted therapy, significantly improved progression-free and overall survival in patients with HER2-positive advanced gastroesophageal adenocarcinoma when used with chemotherapy, with or without a PD-1 inhibitor. 这些结果由Kohei Shithara博士提出, 支持潜在的新一线治疗选项, 挑战Roche的Herceptin。 The results, presented by Dr. Kohei Shitara, support a potential new first-line treatment option, challenging Roche’s Herceptin. Jazz计划于2026年初向林业发展局提交监管申请。 Jazz plans to submit a regulatory application to the FDA in early 2026.